For ovarian malignancy there is no equivalent of a mammogram that might result in early detection and consequently, many diagnoses are late stage, where cancer has already spread. We have set out on a mission to improve and extend the lives of women with late stage ovarian cancer. It is a deeply personal mission for us, as it would be for anyone who’s life and family have been affected by this aggressive cancer. The oncogene we are targeting plays a role from the earliest stages of cancer initiation through its progression and metastatic dissemination. To halt this protein’s function, Tradewind has developed a high-affinity, inhibitory antibody. We are translating our vision into a novel therapeutic approach for cancer.
Tradewind scientists have identified an oncogene that is a little different than the mutated kinases and amplified genes we normally think of as oncogenes. Our first drug target is a secreted protein, that comes to be highly expressed in cancer cells, whereas it is not expressed in adult tissues. It can initiate cancer in transgenic mouse models, enable ascites growth and dissemination to distant organs and is important to maintain tumor cell survival and proliferation in tumors that evolve high expression. Expression correlates with the aggressiveness of human cancer. Our inhibitory antibody binds to this secreted protein and acts like a sponge, holding it is an inactive conformation.
Copyright © 2021 Tradewind BioScience - All Rights Reserved.